South & Central America GMP Cell Therapy Consumables Market

The South & Central America GMP cell therapy consumables market is expected to grow from US$ 584.43 million in 2022 to US$ 2,579.39 million by 2028; it is estimated to grow at a CAGR of 28.0% from 2022 to 2028.

Increasing Clinical Trials and Rising GMP Demand is Fueling the South & Central America GMP Cell Therapy Consumables Market

Cell therapies are constantly evolving, improving, and providing new treatment options for various disorders, such as cancer, autoimmune disorders, and neurological disorders. Immunotherapy is a new approach for cancer treatment. Cell therapies are currently being evaluated in clinical trials for various cancer types, separately and combined with other treatments. Additionally, the cellular immunotherapy targets that are being evaluated in clinical trials, new immunotherapy approaches are also being developed constantly, which is investigated through clinical trials. Since 2017, FDA approved about six chimeric antigen receptor (CAR) T-cell therapies for the treatment of blood cancer, including lymphomas, some leukemia forms, and multiple myeloma. More than 500 CAR-T and 17 chimeric antigen receptor natural killer (CAR-NK) cell trials are currently being conducted across the world, including the four CAR-T cell products—Yescarta, Tecartus, Kymriah, and Breyanzi that are already available in the market. Further, the CAR cellular therapies field is newly developed, and preclinical and clinical studies have already shown remarkable results. It is believed that CAR-based cellular therapies are profoundly promising and will lead the development of approved personalized therapeutic options in the coming years. With new therapeutic modalities emerging in the cell and gene space (CAR-T), companies are required to develop, evaluate, and test these therapies in clinical trials, along with maintaining patient safety. These emerging therapies require a scientific standard of controls and GMPs to ensure patient safety. Thus, it is important to ensure that the equipment used during these processes is compatible with GMP manufacturing environments for cell therapies, and all clinical consumables are manufactured under conditions that fulfil GMP requirements appropriate for the phase and scale of manufacturing. Therefore, the increasing clinical trials among various fields will fuel the South & Central America GMP cell therapy consumables market.

South & Central America GMP Cell Therapy Consumables Market Overview

The South & Central America GMP cell therapy consumables market includes Brazil, Argentina, and the Rest of South & Central America. The region held the smallest portion of the market in the global analysis. The market for cell therapy consumables in the region is expected to have growth opportunities during the forecast period. The GMP cell therapy consumables market in the SAM region is expected to grow owing to factors such as, establishment of pharmaceutical companies in the region, increasing awareness, and rising healthcare expenditure by the countries, the high adoption rate of cell therapy and increased in medical tourism are likely to create demand for GMP cell therapy consumables during the forecast period. Furthermore, increase in research activities and increased use of advanced medicinal products are likely to amplify the market growth.

South & Central America GMP Cell Therapy Consumables Market Revenue and Forecast to 2028 (US$ Million)

South & Central America GMP Cell Therapy Consumables Market Segmentation

The South & Central America GMP cell therapy consumables market is segmented on the basis of product, cell therapy, process, end use, and country.

Based on product, the South & Central America GMP cell therapy consumables market is segmented into kits, reagents/molecular biology reagents, growth factors/cytokines and interleukins (including protein and nucleic acid purification buffers), and others. The kits segment held the largest share of the market in 2022.

Based on cell therapy, the South & Central America GMP cell therapy consumables market is segmented into NK cell therapy, stem cell therapy, T-cell therapy, and others. The T-cell therapy segment registered the largest share of the market in 2022.

Based on process, the South & Central America GMP cell therapy consumables market is segmented into cell collection and characterization/sorting and separation, cell culture and expansion/preparation, cryopreservation, cell processing and formulation, cell isolation and activation, cell distribution/handling, process monitoring and control/readministration/quality assurance, and others. The cell collection and characterization/sorting and separation segment held the largest share of the market in 2022.

Based on end use, the South & Central America GMP cell therapy consumables market is segmented into clinical, commercial, and research. The clinical segment held the largest share of the market in 2022.

Based on country, the South & Central America GMP cell therapy consumables market is segmented into Brazil, Argentina, and the Rest of South & Central America. The Rest of South & Central America dominated the market in 2022.

Bio-Techne Corp, BPS Bioscience Inc, Corning Inc, FUJIFILM Irvine Scientific Inc, Global Life Sciences Solutions USA LLC, Lonza Group AG, Merck KGaA, Miltenyi Biotec BV & Co KG, Sartorius AG, and Thermo Fisher Scientific Inc are the leading companies operating in the South & Central America GMP cell therapy consumables market.

South & Central America GMP Cell Therapy Consumables Market Strategic Insights

South & Central America GMP Cell Therapy Consumables Market Segmentation Analysis

South & Central America GMP Cell Therapy Consumables Market Report Highlights

South & Central America GMP Cell Therapy Consumables Report Scope

South & Central America GMP Cell Therapy Consumables Market Country and Regional Insights